Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and  atherogenic index of plasma in patients  with type 2 diabetes

Abstract

Background The role of serum fibroblast growth factor 19 (FGF19) in the arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to the arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D). Methods 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than that in healthy controls ( p < 0.01). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels ( r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV ( β = –0.20, t = –2.23, p = 0.029) and AIP ( β = –0.28, t = –2.66, p = 0.010) in patients with T2D. Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP in patients with T2D, which indicate serum FGF19 may plays a protect role against pathogenesis of the atherosclerosis in those patients.

New developments in the biology of fibroblast growth factors

“…In contrast, in HFD‐fed ApoE −/− mice, phosphorylation of hepatic farnesoid X receptor by FGF15/19 signaling maintained serum cholesterol levels and protected against atherosclerosis (Byun et al, 2019). In patients with type 2 diabetes (T2D), serum FGF15/19 levels are independently and inversely associated with arteriosclerosis parameters, supporting a protective role for serum FGF15/19 in atherosclerosis progression (W. S. Liu, Tang, et al, 2020). FGF21 also mitigates atherosclerosis in HFD‐fed ApoE −/− mice (Maeng et al, 2020).…”

The ApoB/A-1 ratio is independently associated with subclinical arteriosclerosis and arterial stiffness in type 2 diabetes patients

“…baPWV was related to HbA1c [34], BP, the status of diabetes [35], obesity [36] and arteriosclerosis [17].…”

“…Patients between 20 and 73 years old with a diagnosis of type 2 diabetes [19] and who underwent baPWV, ABI and carotid B-ultrasonography were enrolled to participate. A well-trained examiner collected the information of the patients via their clinal records, including sex, age, sex, duration, waist circumference, blood pressure, body mass index (BMI: weight (kg)/height (m) squared), history of cardiovascular events, dyslipidemia [20], hypertension [17], medical history (statin use), antidiabetic treatment (lifestyle alone, insulin treatment, insulin secretagogues, insulin sensitizers, metformin, glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors (DPP-4Is), and sodium-glucose cotransporter-2 inhibitors (SGL-2Is)). These patients were excluded if they had a history of CAD, abnormal liver function, severe renal disease, previous tumor, or acute diabetic complications (diabetic ketoacidosis).…”

“…The report suggested that ABI and carotid atherosclerosis participate in the atherosis process, while baPWV participates in the sclerosis process [15]. Although many clinical and basic studies have suggested that ABI, carotid atherosclerosis and baPWV are independent predictors of CAD and are related to the incidence and mortality of CAD [13,16,17], there are few reports on the relationship between these parameters and atherogenic dyslipidemia, especially the ApoB/A1. Previous studies found that ApoB/A1 ratio may be an indicator in predicting T2D [18] and that this ratio was obviously related to carotid atherosclerosis in T2D patients with normal LDL-C levels [11].…”